#gland pharma

[gland-pharma-limited]

Gland pharma - Annual report

[gland-pharma-limited]

Gland Pharma Limited adopts direct marketing for our B2C operations through a field force of employees and a distribution network that connects with corporate hospitals, government health centers, nursing homes and offers a vast array of niche products across several therapeutic segments.

A CDMO pharmaceutical company and maker of injectables, Gland Pharma Limited uses a field team of employees and a distribution network to conduct business with consumers exclusively in India.

[futurecapstocks]

Market this week 12-11-2022

Market this week 12-11-2022

Despite smaller provisions, the Q2 net disappoints the street, sending LIC Housing down 10%. On November 2, shares of LIC Housing, the nation’s second-largest provider of housing finance, achieved a 10-percent decline, marking the company’s steepest decline in more than two years. The 23 percent year-over-year increase in net profit at Rs 305 crore appears to have disappointed market players, as…

View On WordPress

[shlipayadavblog]

Gland Pharma rides high on valuation comfort, strong growth prospects

The stock of generic injectables major Gland Pharma is down 23 per cent since its highs in April this year. The stock has been under pressure on worries of gross margin pressures, component shortages and possibility of an equity stake sale by earlier promoters.

[technomoz]

Gland Pharma looks at complex injectables, biosimilars

Gland Pharma looks at complex injectables, biosimilars

Primarily operating under a business model, Gland Pharma is looking into the complex injectables sector, developing contracts, and manufacturing biosimilars to support its near-term growth. The Hyderabad-based pharmaceutical company indicated that it has made good progress in research and development for the planned introduction batches of complex injections to be introduced in the current…

View On WordPress

[investyadnya]

Top 5 Pharma Stocks- Quantitative Analysis

Top 5 Pharma Stocks- Quantitative Analysis

Introduction: According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the next decade. India’s domestic pharmaceutical market is estimated at US$ 42 billion in 2021 and likely to reach US$ 65 billion by 2024 and further expand to reach ~US$ 120-130 billion by 2030. India’s biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture,…

View On WordPress